Monoclonal mouse anti human pd l1 clone 22c3

Manufactured by Agilent Technologies

Sourced in United States

The Monoclonal Mouse Anti-Human PD-L1 clone 22C3 is a laboratory reagent used for the detection and analysis of the PD-L1 protein in biological samples. This product is a monoclonal antibody that specifically binds to the PD-L1 protein expressed on human cells.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

Anti-PD-L1 (Clone 22C3, PD-L1 (clone 22C3, Anti-human PD-L1 Anti-PD-L1 Clone 22C3 PD-L1 Anti-TM

2 protocols using monoclonal mouse anti human pd l1 clone 22c3

PD-L1 Expression Analysis by IHC

Check if the same lab product or an alternative is used in the 5 most similar protocols

PD-L1 was analyzed by immunohistochemistry (IHC) in the Pathology Department of TJMUCH using the Monoclonal Mouse Anti-Human PD-L1 clone 22C3 (LOT10145059, Dako, Carpentaria, CA, USA). The tumor proportion score (TPS) and combined positivity score (CPS) were calculated as the percentage of at least 100 viable cells with complete or partial membrane staining. In patients with no residual tumor after the treatment, only the CPS was calculated. Interpretation of TPS and CPS of patients was provided by a pathologist at TJMUCH.

Chen Y., Yan B., Xu F., Hui Z., Zhao G., Liu J., Zhang H., Zeng Z., Zhang R., Provencio M., Ren X, & You J. (2021). Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer. Translational Lung Cancer Research, 10(5), 2193-2204.

+ Open protocol

+ Expand

PD-L1 Expression Analysis by IHC

Check if the same lab product or an alternative is used in the 5 most similar protocols

The expression of PD-L1 was analyzed by immunohistochemistry (IHC) using monoclonal mouse anti-human PD-L1 clone 22C3 (Dako, Agilent Technologies, CA, USA) on the pretreatment biopsy samples. The tumor proportion score (TPS) were assessed as the percentage of at least 100 viable tumor cells.

Du C., Chen Y., Zhou Y., Zheng D., Zhao J., Tang J., Wu Y, & Tu Z. (2023). Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC. BMC Cancer, 23, 1260.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!